Maternal RSV vaccines found to cut infection risk

Vaccinating pregnant women against RSV reduced the risk of infection in their infants by 61% compared with newborns with unvaccinated mothers, new data from Epic Research shows.

Why it matters: RSV is most common cause of hospitalization of children under the age of 1 in the U.S. The Food and Drug Administration in 2023 approved Pfizer's Abrysvo for use from 32 to 36 weeks into a pregnancy.